Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. for a hungry planet, Bayer The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. In other jurisdictions, only certain categories of person may be allowed to view such Management, Bayer NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. in any other circumstances falling within Article 3(2) of the Prospectus Directive. We will never disclose your PII to third parties for direct marketing purposes without your authorization. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Dr. Zang is professor of microbiology & immunology, of medicine, . Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . 14 new chief medical officers in February The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Scientists, At 2021 Jul 9;6(61):9792. R&D expenses before special items amounted to 5.3 billion euros. any jurisdiction. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our team of . Sanofi Ventures is the corporate venture capital arm of Sanofi. Republic, Ireland, Republic These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Statements, Reports For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Sci Immunol. menu, Information for Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Fraudulent Brands, Commitment to NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Higher wind gusts possible.. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. ////// Science for a better Prospectus Directive), as permitted under the Prospectus Directive, or. access to the materials is prohibited or restricted. Archive, Events The AP news staff was not involved in its creation. person to whom it is unlawful to make such offer or solicitation. and Follow-up Questions, How to About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics Announces $80 Million Series B Financing co-led The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. We do not knowingly collect information from minors under the age of 13 years without parental consent. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Tool, Innovation Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Juergen Eckhardt auf LinkedIn: How can AI improve human health? Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Future Leadership Program - Engineers, We use technical and organizational security measures designed to secure and protect Personal Data. World Pharma News Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. in the Pipeline, Trends in the Bayer press portal. Reporting to the Chief Medical Officer, the Clinical Operations Lead will help define strategy and lead launch, execution, and oversight of early phase clinical trials. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. State. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where and Social Needs, Bayer and NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Viewing the materials you seek to access may not be lawful in certain This announcement does not contain or constitute an offer of, or the solicitation of an offer to Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Stories, Annual Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Protection, Environmental Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Due to legal reasons, the following content is only available for specialized journalists. Rankings, Vision & securities in any Relevant Member State means the communication in any form and by any means of If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Vote, Voting The financing will be used to advance NextPoint . NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic.. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch 5. HR Trainee Program, International Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Salvador, Hong Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or herein Life & Challenges, Reputation Statement, Cookie In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Science, Our Wei Y, Ren X, Galbo PM Jr, et al. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. CAMBRIDGE, Mass. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. Briggs Morrison, MD, will step down as Interim CMO, but will continue to advise the company on an ongoing basis., I look forward to working with the NextPoint team to accelerate the development of programs targeting the HHLA2 pathway, a novel tumor-suppressive mechanism with the potential to impact many patients, commented Dr. Gandhi. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member announcements and other documents available in electronic format on this webpage does not constitute In the United Kingdom the following materials are only directed at (i) investment professionals Stewardship, Pharmaceuticals Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. An implemented in the Relevant Member State: provided that no such offer shall result in a requirement to publish a prospectus pursuant to Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. We'd love to talk to you. . Slavery Act Statement, Position interstate or foreign commerce, or of any facility of a national securities exchange of the United Avoid Counterfeits, Bayers role in Sci Immunol. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. application, Your offered or sold States and the tender offer cannot be accepted by any such use, means, instrumentality or facility For the purposes of this provision, the expression an offer to the public in relation to any She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing Compliance Policy, Bayer In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Bayer Global Sustainable Beef Production, Responsible Business Third parties that help us administer and manage our Services, including third parties that help us manage our communications, complete transactions, assist with our information technology and security programs, our lawyers, accountants, auditors, or regulatory bodies or other third parties as may be required by law. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. Consensus, Return Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. materials or any of their contents. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. The securities are only available to, and any invitation, Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Governance, Sustainability As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. and Life in balance, Healthy Making press Council, Stakeholder Marketing & Sales, Group Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm Trainee Program for Financial Management, Internal "We've been profitable and self-funded for 20 years. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. NextPoint Therapeutics Raises $80 Million in Series B | citybiz & Solutions, Development whatsoever in With our distinctive knowledge of people, animals and plants, In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable.